Formulated for hyperthyroidism to manage hormone production and support endocrine stability.
Mechanism of Action
NeoMercazole is a prodrug of methimazole. It inhibits the enzyme thyroid peroxidase, which prevents the coupling of iodotyrosines and the subsequent synthesis of T3 and T4 hormones in the thyroid gland.
Route of Administration
Oral
Onset Time
1–3 weeks
Duration
6–8 hours (methimazole half-life)
Contraindications
History of severe blood dyscrasias, Severe hepatic impairment, Hypersensitivity to carbimazole
Severe Adverse Events
Agranulocytosis, Hepatotoxicity, Pancreatitis — requires immediate medical attention
Common Side Effects
Nausea, Headache, Arthralgia
Uncommon Side Effects
Rash, Pruritus, Taste perversion
Drug Interactions
Alcohol, Warfarin, Digoxin, Theophylline
Pregnancy Safety Warnings
FDA Category D: High risk of fetal malformation. Breastfeeding: Excreted in milk; monitor infant thyroid.
Age Restrictions
Safety and efficacy established in pediatric patients; requires dose monitoring.
Information related to NeoMercazole is compiled and periodically reviewed with reference to established medical sources and prescribing guidance. Content is provided for general reference and should be confirmed with a registered healthcare professional before use.
